FSTX | tickerfilter.com

Fundamental analysis

57%

Profitability 68%

Dept financing 0%

Liquidity 0%

Performance 75%

Performance

5 Days

-6.62%

1 Month

14.58%

3 Months

-2.14%

6 Months

-18.03%

1 Year

89.00%

2 Year

-36.64%

Key data

Stock price

$7.12

P/E Ratio

0.00

DAY RANGE

N/A - $7.12

EPS

$0.00

52 WEEK RANGE

$2.07 - $6.93

52 WEEK CHANGE

$0.92

MARKET CAP

120.901 M

YIELD

N/A

SHARES OUTSTANDING

21.982 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$351,853

AVERAGE 30 VOLUME

$319,729

Company detail

CEO:
Region: US
Website: f-star.com
Employees: 77
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.

FSTX - F-star Therapeutics Inc